Noble Financial analyst Cosme Ordonez initiated coverage with a Buy rating on Genprex Inc (GNPX – Research Report) on April 26 and set a price target of $5. The company’s shares closed on Friday at $1.78, close to its 52-week low of $0.95.

The the analyst consensus on Genprex Inc is currently a Hold rating.

See today’s analyst top recommended stocks >>

Based on Genprex Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $3.43 million. In comparison, last year the company had a GAAP net loss of $694K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Genprex, Inc. is a clinical stage gene therapy company, which engages in the development of novel proprietary technology platform for the treatment of cancer. It develops the Oncoprex immunogene therapy which targets the non-small cell lung cancer and other solid tumors.